dc.contributor |
Háskóli Íslands |
dc.contributor |
University of Iceland |
dc.contributor.author |
Chatzidionysiou, Katerina |
dc.contributor.author |
Delcoigne, Bénédicte |
dc.contributor.author |
Frisell, Thomas |
dc.contributor.author |
Hetland, Merete L |
dc.contributor.author |
Glintborg, Bente |
dc.contributor.author |
dreyer, lene |
dc.contributor.author |
Cordtz, René |
dc.contributor.author |
Zobbe, Kristian |
dc.contributor.author |
Nordström, Dan |
dc.contributor.author |
Trokovic, Nina |
dc.contributor.author |
Aaltonen, Kalle |
dc.contributor.author |
Provan, Sella Aarrestad |
dc.contributor.author |
Gröndal, Gerður |
dc.contributor.author |
Gudbjornsson, Bjorn |
dc.contributor.author |
Askling, Johan |
dc.date.accessioned |
2020-11-13T14:15:39Z |
dc.date.available |
2020-11-13T14:15:39Z |
dc.date.issued |
2020-09-08 |
dc.identifier.citation |
Chatzidionysiou K, Delcoigne B, Frisell T, et alHow do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registersRMD Open 2020;6:e001363. doi: 10.1136/rmdopen-2020-001363 |
dc.identifier.issn |
2056-5933 |
dc.identifier.uri |
https://hdl.handle.net/20.500.11815/2202 |
dc.description |
Publisher's version (útgefin grein) |
dc.description.abstract |
[No abstract available] |
dc.description.sponsorship |
This study was partly funded by grants from Nord-Forsk and FOREUM. |
dc.format.extent |
e001363 |
dc.language.iso |
en |
dc.publisher |
BMJ |
dc.relation.ispartofseries |
RMD Open;6(2) |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.subject |
Arthritis |
dc.subject |
Biological Therapy |
dc.subject |
Epidemiology |
dc.subject |
Rheumatoid |
dc.subject |
Iktsýki |
dc.subject |
Líftæknilyf |
dc.title |
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers |
dc.type |
info:eu-repo/semantics/article |
dcterms.license |
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
dc.description.version |
Peer Reviewed |
dc.identifier.journal |
RMD Open |
dc.identifier.doi |
10.1136/rmdopen-2020-001363 |
dc.relation.url |
https://syndication.highwire.org/content/doi/10.1136/rmdopen-2020-001363 |
dc.contributor.department |
Læknadeild (HÍ) |
dc.contributor.department |
Faculty of Medicine (UI) |
dc.contributor.school |
Heilbrigðisvísindasvið (HÍ) |
dc.contributor.school |
School of Health Sciences (UI) |